Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized-withdrawal study of PF-04965842 in moderate to severe atopic dermatitis
NL-OMON48910Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (5 arms), sponsored by Pfizer. Started Apr 2019; status: active, not recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON48910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48910.